Patents Assigned to Pfizer
  • Phosphodiesterase enzymes
    Publication number: 20040126863
    Abstract: Amino acid sequences and nucleotide sequences relating to PDEXV are described. In a preferred aspect, the amino acid sequence comprises the sequence presented as SEQ ID NO:1.
    Type: Application
    Filed: December 24, 2003
    Publication date: July 1, 2004
    Applicant: Pfizer Inc
    Inventors: Mark D. Fidock, Nicola M. Robas
  • Nicotinamide derivatives useful as PDE4 inhibitors
    Patent number: 6756392
    Abstract: The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions as well as for wounds healing.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: June 29, 2004
    Assignee: Pfizer Inc
    Inventor: Thomas V. Magee
  • Benzothiophenes and related compounds as estrogen agonists
    Patent number: 6756388
    Abstract: The invention is a compound of Formula (I): wherein R is —OH, R1 is —OH, R2 is —H, n is 2 or 3 and X is sulfur, or a pharmaceutically acceptable salt of a compound having Formula (1), or a pharmaceutical composition comprising a compound having Formula (1) or a pharmaceutically acceptable salt thereof, or methods of treating bone loss, breast cancer or prostate cancer comprising administering an effective amount of the compound having Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 1, 1996
    Date of Patent: June 29, 2004
    Assignee: Pfizer Inc.
    Inventors: Kimberly O. Cameron, Paul Da Silva-Jardine, Eric R. Larson, James R. Hauske, Robert L. Rosati
  • Imidazole derivatives
    Patent number: 6756385
    Abstract: The invention provides compounds of formula 1 wherein R1, R2, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: June 29, 2004
    Assignee: Pfizer Inc.
    Inventors: Mark A. Sanner, Chris J. Helal, Christoper B. Cooper, Frank S. Menniti, Michael K. Ahlijanian, Annabella Villalobos, Lit-Fui Lau, Patricia A. Seymour
  • Pharmaceutically active compounds
    Patent number: 6756373
    Abstract: There is provided a compound of formula I: wherein X represents O or NR5 R4 represents H, halo, cyano, nitro, halo(loweralkyl), OR6, OC(O)R7, C(O)R8, C(O)OR9, C(O)NR10R11, NR12R13, NR16Y(O)R17, N[Y(O)R17]2, SOR18, SO2R19, C(O)AZ, lower alkyl, lower alkenyl, lower alkynyl, Het, alkylHet, aryl, alkylaryl (which latter seven groups are all optionally substituted with one or more substituents selected from halo, cyano, nitro, lower alkyl, halo(loweralkyl), OR6, OC(O)R7, C(O)R8, C(O)OR9, C(O)NR10R11, NR12R13 and SO2NR14R15) which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g., cGMP PDE5) is desired.
    Type: Grant
    Filed: October 6, 2000
    Date of Patent: June 29, 2004
    Assignee: Pfizer Inc.
    Inventors: Charlotte Moira Norfor Allerton, Christopher Gordon Barber, Graham Nigel Maw, David James Rawson
  • Compositions and methods for treating osteoporosis and lowering cholesterol
    Patent number: 6756401
    Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in promoting bone formation and/or preventing bone loss and lowering blood cholesterol. The compositions are comprised of an estrogen agonist/antagonist as a first active component and a statin as a second active component and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: June 29, 2004
    Assignee: Pfizer Inc.
    Inventors: Wesley W. Day, Andrew G. Lee, David D. Thompson
  • Use of growth hormone secretagogues for treatment of physical performance decline
    Publication number: 20040122062
    Abstract: This invention is directed to methods for treating age-related decline in physical performance which comprises administering a growth hormone secretagogue, a prodrug thereof or a pharmaceutically acceptable salt of said secretagogue or said prodrug.
    Type: Application
    Filed: November 24, 2003
    Publication date: June 24, 2004
    Applicant: Pfizer Inc
    Inventors: David B. MacLean, William H. Landschulz
  • Controlled-Release of an active substance into a high fat environment
    Publication number: 20040121015
    Abstract: A controlled release delivery composition which can be administered to a high fat use environment such as the human gastrointestinal tract following a high fat meal. The delivery composition is embodied as a core surrounded by an asymmetric polymeric membrane. In a preferred embodiment, the asymmetric polymeric membrane is cellulose acetate.
    Type: Application
    Filed: December 3, 2003
    Publication date: June 24, 2004
    Applicant: Pfizer Inc
    Inventors: Mark B. Chidlaw, Dwayne T. Friesen, Scott M. Herbig, James A.S. Nightingale, Cynthia A. Oksanen, James B. West
  • Stable non-dihydrate azithromycin oral suspensions
    Publication number: 20040121966
    Abstract: This invention relates to a powder for oral suspension, and an oral suspension made therefrom, which comprises a n-propanol solvate of non-dihydrate azithromycin and an azithromycin conversion stabilizing excipient, wherein said excipient reduces the conversion of the form of azithromycin, when placed in suspension, to another form of azithromycin.
    Type: Application
    Filed: July 15, 2003
    Publication date: June 24, 2004
    Applicant: Pfizer Inc.
    Inventors: Zheng J. Li, Andrew V. Trask
  • NPY-5 antagonists
    Publication number: 20040122038
    Abstract: The present invention provides NPY-5 receptor antagonists having a Formula (I) 1
    Type: Application
    Filed: December 1, 2003
    Publication date: June 24, 2004
    Applicant: Pfizer Inc
    Inventor: Marlys Hammond
  • NPY-5 antagonists
    Publication number: 20040122046
    Abstract: The present invention provides NPY-5 receptor antagonists having a Formula (IA) 1
    Type: Application
    Filed: December 1, 2003
    Publication date: June 24, 2004
    Applicant: Pfizer Inc
    Inventor: Richard L. Elliott
  • Cannabinoid receptor ligands and uses thereof
    Publication number: 20040122074
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment diseases, conditions and/or disorders modulated by cannabinoid receptor antagonists in animals are described herein.
    Type: Application
    Filed: November 4, 2003
    Publication date: June 24, 2004
    Applicant: Pfizer Inc.
    Inventors: Robert L. Dow, Marlys Hammond
  • Imidazopyridine compounds as 5-HT4 receptor agonists
    Publication number: 20040122043
    Abstract: This invention provides a compound of the formula (I): 1
    Type: Application
    Filed: September 17, 2003
    Publication date: June 24, 2004
    Applicant: Pfizer Inc
    Inventors: Satoru Iguchi, Yasuhiro Katsu, Kana Kon-I, Hirohide Noguchi, Chikara Uchida
  • Treatment of neuropathy
    Publication number: 20040122010
    Abstract: This invention relates to the use of cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of neuropathy, including in particular the treatment of diabetic neuropathy.
    Type: Application
    Filed: December 10, 2003
    Publication date: June 24, 2004
    Applicant: Pfizer Inc
    Inventors: Eric B. Grossman, Nandan P. Koppiker, Steven B. Leichter
  • Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
    Publication number: 20040122226
    Abstract: Methods for the preparation of N-arylated oxazolidinone compounds via a copper catalyzed cross coupling reaction are disclosed.
    Type: Application
    Filed: August 21, 2003
    Publication date: June 24, 2004
    Applicant: Pfizer Inc
    Inventors: Arun Ghosh, Stephane Caron, Janice E. Sieser
  • Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents
    Patent number: 6753332
    Abstract: The present invention relates to compounds of the formula wherein R1, R3, R5 and A are defined as in the specification, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the invention are useful in the treatment of inflammation and other inflammation associated disorders, such as osteoarthritis, rheumatoid arthritis, colon cancer and Alzheimer's disease, in mammals (preferably humans, dogs, cats and livestock).
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: June 22, 2004
    Assignee: Pfizer, Inc.
    Inventors: Subas M. Sakya, Andrei Shavnya, Bryson Rast
  • Preparation of sodium-hydrogen exchanger type-1 inhibitors
    Patent number: 6753334
    Abstract: This invention relates to methods of preparing sodium-hydrogen exchanger type 1 (NHE-1) inhibitors of formula I′ intermediates of the NHE-1 inhibitors and a new almost colorless form of the NHE-1 inhibitor N-(5-cyclopropyl-1-quinolin-5-yl-1H-pyrazole-4-carbonyl)-guanidine.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: June 22, 2004
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: John F. Lambert, Timothy Norris
  • 2-aminocarbonyl-9H-purine derivatives
    Patent number: 6753322
    Abstract: The present invention relates to compounds of the formula: and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.
    Type: Grant
    Filed: June 5, 2001
    Date of Patent: June 22, 2004
    Assignee: Pfizer Inc
    Inventors: Simon John Mantell, Peter Thomas Stephenson
  • Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors
    Publication number: 20040116473
    Abstract: Novel isothiazole and isoxazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer, and fibrotic diseases.
    Type: Application
    Filed: September 17, 2003
    Publication date: June 17, 2004
    Applicant: Pfizer Inc
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Method of inducing euglycemia in diabetic patients
    Publication number: 20040112376
    Abstract: Inhaled insulin, relative to subcutaneously and/or transdermally administered insulin, can be used to reduce hepatic glucose output in fasted diabetic patients.
    Type: Application
    Filed: December 4, 2003
    Publication date: June 17, 2004
    Applicant: Pfizer Inc
    Inventors: Rochelle L. Chaiken, Thomas R. Strack